A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed. METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa(200)MZ) or 4 months (...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Tuberc Lung Dis
Main Authors: Tweed, C. D., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V., Ban, A. Y.L., Bateson, A. L.C., Betteridge, M. C., Brumskine, W., Caoili, J., Chaisson, R. E., Cevik, M., Conradie, F., Dawson, R., del Parigi, A., Diacon, A., Everitt, D. E., Fabiane, S.M., Hunt, R., Ismail, A. I., Lalloo, U., Lombard, L., Louw, C., Malahleha, M., McHugh, T. D., Mendel, C. M., Mhimbira, F., Moodliar, R. N., Nduba, V., Nunn, A. J., Sabi, I., Sebe, M. A., Selepe, R. A. P., Staples, S., Swindells, S., van Niekerk, C. H., Variava, E., Spigelman, M., Gillespie, S. H.
Formato: Artigo
Idioma:Inglês
Publicado: International Union Against Tuberculosis and Lung Disease 2021
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8009598/
https://ncbi.nlm.nih.gov/pubmed/33762075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.20.0513
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares